ReviewCurrent osteoporosis reports2018
Osteoblastic Factors in Prostate Cancer Bone Metastasis.
Review in Current osteoporosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 76 citations in OpenAlex.
- Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles.Journal of extracellular vesicles · 2026Article
- Differential Effects of a First-in-Class IKKCalcified tissue international · 2026Article
- Transparent chest radiograph foundation model enables explainable human disease profiling.NPJ digital medicine · 2026Article
- Insulin-like growth factor-binding protein 5 promotes prostate cancer metastasis and osteoblastic activity by inducing chemokines and activating NF-κB signaling.Cancer cell international · 2026Article
- Review
- Modeling the effects of radiation on the bone tumor microenvironment: opportunities for exploring combination therapies in microphysiologic systems.Cellular & molecular biology letters · 2025Review
- Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer.Molecular cancer research : MCR · 2025Article
- Potential Molecular Interactions and In Vitro Hyperthermia, Thermal, and Magnetic Studies of Bioactive Nickel-Doped Hydroxyapatite Thin Films.International journal of molecular sciences · 2025Article
- Radiographic Assessment of Osteosclerotic Lesions in Mice with Bone Metastasis.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Review
- Artificial Intelligence and Radiomics Applied to Prostate Cancer Bone Metastasis Imaging: A Review.iRadiology · 2024Article
- The Link Between the Gut Microbiome and Bone Metastasis.International journal of molecular sciences · 2024Review
- Immune mediated support of metastasis: Implication for bone invasion.Cancer communications (London, England) · 2024Review
- Cell-cell communication characteristics in breast cancer metastasis.Cell communication and signaling : CCS · 2024Review
- Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer.Frontiers in immunology · 2024Article
- Article
- Distinguishable Colorimetric Biosensor for Diagnosis of Prostate Cancer Bone Metastases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- The role of E3 ubiquitin ligases in bone homeostasis and related diseases.Acta pharmaceutica Sinica. B · 2023Review
- Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer.Nutrients · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewProstate cancer bone metastasis is the lethal progression of the disease. The disease frequently presents with osteoblastic lesions in bone. The tumor-induced bone can cause complications that significantly hamper the quality of life of patients. A better understanding of how prostate cancer induces aberrant bone formation and how the aberrant bone affects the progression and treatment of the disease may improve the therapies for this disease. RECENT
findingsProstate cancer-induced bone was shown to enhance tumor growth and confer therapeutic resistance in bone metastasis. Clinically, Radium-223, an alpha emitter that selectively targets bone, was shown to improve overall survival in patients, supporting a role of tumor-induced bone in prostate cancer progression in bone. Recently, it was discovered that PCa-induced aberrant bone formation is due, in part, from tumor-associated endothelial cells that were converted into osteoblasts through endothelial-to-osteoblast (EC-to-OSB) conversion by tumor-secreted BMP4. The unique bone-forming phenotype of prostate cancer bone metastasis plays a role in prostate cancer progression in bone and therapy resistance. Therapies that incorporate targeting the tumor-induced osteoblasts or EC-to-OSB conversion mechanism may reduce tumor-induced bone formation and improve therapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.